Zhiyi Pharmaceutics focuses on the research and development of second-generation probiotics and Live Biotherapeutics.
Founded in 2013, Zhiyi Bio focuses on the research and development of second-generation probiotics and Live Biotherapeutics. Based on the discovery of strains and drug development with independent intellectual property rights, a lot of innovative research has been carried out, and the “Know-How” from strains to drugs has been established, and the innovative live bacteria drug SK08 is about to enter the clinic. On this basis, Zhiyi will continue to strengthen the research and development of the relationship between human microbiome and disease, including microbial culture group and pathobionts research, target determination and separation of new functional strains.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 4, 2022 | Series B | ¥300M | 1 | — | — | Detail |
Sep 22, 2021 | Series B | — | 1 | — | — | Detail |
Dec 23, 2020 | Series B | ¥110M | 3 | — | — | Detail |
Sep 5, 2018 | Series A | ¥50M | 3 | — | — | Detail |
Sep 6, 2017 | Angel | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
SDIC Venture Capital | — | Series B |
Kingsum Capital | — | Series B |
Zhuhai Hengqin Lehong Investment Management | — | Series B |
Korea Investment Holdings | — | Series B |
Shangdong Meiyu | — | Series A |
Qingkong Jinxin Blue Microbiology Fund | — | Series A |
Shenzhen Capital Group | — | Series A |
Hejun Capital | — | Angel |